Follow the people · Insider
Joanne M. Donovan
Joanne M. Donovan files insider transactions with the SEC as a cmo of Edgewise Therapeutics (EWTX). We hold 7 disclosed purchases and sales filed since 30 June 2015, 2 of them in the last 90 days.
- Files forEWTX
- Disclosed buys and sells7 in all, 2 in the last 90 days
- Last disclosure14 August 2026
Positions held
2 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 30 April 2021 — 13 August 2026Cmo · Edgewise Therapeutics (EWTX)54 Form 4 lines · source: SEC Form 4
- Filed 30 June 2015 — 12 February 2020CMO; SVP Clinical Development · Catabasis Pharmaceuticals (CATB)10 Form 4 lines · source: SEC Form 4
Everything they disclosed
64 entries, newest first — one per disclosure report, one per Form 4 line- was granted 65,000 shares of Edgewise Therapeutics (a derivative holding)SEC Form 417 August 2026Stock Option (Right to Buy) · traded 12 August 2026 · filed 17 August 2026
- exercised options over 5,781 shares of Edgewise TherapeuticsSEC Form 414 August 2026Common Stock · traded 12 August 2026 · filed 14 August 2026
- was granted 32,500 shares of Edgewise Therapeutics (a derivative holding)SEC Form 414 August 2026Restricted Stock Units · traded 12 August 2026 · filed 14 August 2026
- was granted 65,000 shares of Edgewise Therapeutics (a derivative holding)SEC Form 414 August 2026Stock Option (Right to Buy) · traded 12 August 2026 · filed 14 August 2026
- exercised options over 7,031 shares of Edgewise TherapeuticsSEC Form 414 August 2026Common Stock · traded 12 August 2026 · filed 14 August 2026
- ▼ sold on the open market 2,839 shares of Edgewise TherapeuticsSEC Form 414 August 2026Common Stock · traded 12 August 2026 · filed 14 August 2026
- ▼ sold on the open market 2,779 shares of Edgewise TherapeuticsSEC Form 414 August 2026Common Stock · traded 12 August 2026 · filed 14 August 2026
- ▼ sold on the open market 104 shares of Edgewise TherapeuticsSEC Form 414 August 2026Common Stock · traded 12 August 2026 · filed 14 August 2026
- ▼ sold on the open market 800 shares of Edgewise TherapeuticsSEC Form 414 August 2026Common Stock · traded 12 August 2026 · filed 14 August 2026
- ▼ sold on the open market 2,919 shares of Edgewise TherapeuticsSEC Form 414 August 2026Common Stock · traded 13 August 2026 · filed 14 August 2026
- exercised options over 5,781 shares of Edgewise Therapeutics (a derivative holding)SEC Form 414 August 2026Restricted Stock Units · traded 12 August 2026 · filed 14 August 2026
- exercised options over 7,031 shares of Edgewise Therapeutics (a derivative holding)SEC Form 414 August 2026Restricted Stock Units · traded 12 August 2026 · filed 14 August 2026
- ▼ sold on the open market 5,230 shares of Edgewise TherapeuticsSEC Form 45 May 2026Common Stock · traded 4 May 2026 · filed 5 May 2026
- exercised options over 50,000 shares of Edgewise TherapeuticsSEC Form 45 May 2026Common Stock · traded 5 May 2026 · filed 5 May 2026
- ▼ sold on the open market 50,000 shares of Edgewise TherapeuticsSEC Form 45 May 2026Common Stock · traded 5 May 2026 · filed 5 May 2026
- exercised options over 50,000 shares of Edgewise Therapeutics (a derivative holding)SEC Form 45 May 2026Stock Option (Right to Buy) · traded 5 May 2026 · filed 5 May 2026
- exercised options over 28,662 shares of Edgewise TherapeuticsSEC Form 42 April 2026Common Stock · traded 1 April 2026 · filed 2 April 2026
- ▼ sold on the open market 28,662 shares of Edgewise TherapeuticsSEC Form 42 April 2026Common Stock · traded 1 April 2026 · filed 2 April 2026
- exercised options over 28,662 shares of Edgewise Therapeutics (a derivative holding)SEC Form 42 April 2026Stock Option (Right to Buy) · traded 1 April 2026 · filed 2 April 2026
- exercised options over 21,338 shares of Edgewise TherapeuticsSEC Form 431 March 2026Common Stock · traded 31 March 2026 · filed 31 March 2026
- ▼ sold on the open market 21,338 shares of Edgewise TherapeuticsSEC Form 431 March 2026Common Stock · traded 31 March 2026 · filed 31 March 2026
- exercised options over 21,338 shares of Edgewise Therapeutics (a derivative holding)SEC Form 431 March 2026Stock Option (Right to Buy) · traded 31 March 2026 · filed 31 March 2026
- exercised options over 21,338 shares of Edgewise Therapeutics (a derivative holding)SEC Form 431 March 2026Stock Option (Right to Buy) · traded 31 March 2026 · filed 31 March 2026
- exercised options over 21,338 shares of Edgewise TherapeuticsSEC Form 431 March 2026Common Stock · traded 31 March 2026 · filed 31 March 2026
- ▼ sold on the open market 21,338 shares of Edgewise TherapeuticsSEC Form 431 March 2026Common Stock · traded 31 March 2026 · filed 31 March 2026
- ▼ sold on the open market 9,623 shares of Edgewise TherapeuticsSEC Form 430 March 2026Common Stock · traded 27 March 2026 · filed 30 March 2026
- ▼ sold on the open market 6,735 shares of Edgewise TherapeuticsSEC Form 430 March 2026Common Stock · traded 27 March 2026 · filed 30 March 2026
- ▼ sold on the open market 9,623 shares of Edgewise TherapeuticsSEC Form 430 March 2026Common Stock · traded 27 March 2026 · filed 30 March 2026
- ▼ sold on the open market 6,735 shares of Edgewise TherapeuticsSEC Form 430 March 2026Common Stock · traded 27 March 2026 · filed 30 March 2026
- exercised options over 5,781 shares of Edgewise Therapeutics (a derivative holding)SEC Form 414 August 2025Restricted Stock Units · traded 12 August 2025 · filed 14 August 2025
- was granted 28,125 shares of Edgewise Therapeutics (a derivative holding)SEC Form 414 August 2025Restricted Stock Units · traded 12 August 2025 · filed 14 August 2025
- was granted 168,750 shares of Edgewise Therapeutics (a derivative holding)SEC Form 414 August 2025Stock Option (Right to Buy) · traded 12 August 2025 · filed 14 August 2025
- exercised options over 5,781 shares of Edgewise TherapeuticsSEC Form 414 August 2025Common Stock · traded 12 August 2025 · filed 14 August 2025
- ▼ sold on the open market 2,862 shares of Edgewise TherapeuticsSEC Form 414 August 2025Common Stock · traded 12 August 2025 · filed 14 August 2025
- exercised options over 10,417 shares of Edgewise Therapeutics (a derivative holding)SEC Form 47 May 2025Restricted Stock Units · traded 1 May 2025 · filed 7 May 2025
- exercised options over 10,417 shares of Edgewise TherapeuticsSEC Form 47 May 2025Common Stock · traded 1 May 2025 · filed 7 May 2025
- ▼ sold on the open market 5,187 shares of Edgewise TherapeuticsSEC Form 47 May 2025Common Stock · traded 2 May 2025 · filed 7 May 2025
- exercised options over 25,000 shares of Edgewise Therapeutics (a derivative holding)SEC Form 430 January 2025Stock Option (Right to Buy) · traded 28 January 2025 · filed 30 January 2025
- exercised options over 25,000 shares of Edgewise TherapeuticsSEC Form 430 January 2025Common Stock · traded 28 January 2025 · filed 30 January 2025
- ▼ sold on the open market 25,000 shares of Edgewise TherapeuticsSEC Form 430 January 2025Common Stock · traded 28 January 2025 · filed 30 January 2025
- ▼ sold on the open market 7,162 shares of Edgewise TherapeuticsSEC Form 424 September 2024Common Stock · traded 20 September 2024 · filed 24 September 2024
- was granted 138,750 shares of Edgewise Therapeutics (a derivative holding)SEC Form 414 August 2024Stock Option (Right to Buy) · traded 12 August 2024 · filed 14 August 2024
- was granted 23,125 shares of Edgewise Therapeutics (a derivative holding)SEC Form 414 August 2024Restricted Stock Units · traded 12 August 2024 · filed 14 August 2024
- exercised options over 10,417 shares of Edgewise Therapeutics (a derivative holding)SEC Form 43 May 2024Restricted Stock Units · traded 1 May 2024 · filed 3 May 2024
- exercised options over 10,417 shares of Edgewise TherapeuticsSEC Form 43 May 2024Common Stock · traded 1 May 2024 · filed 3 May 2024
- ▼ sold on the open market 3,682 shares of Edgewise TherapeuticsSEC Form 43 May 2024Common Stock · traded 2 May 2024 · filed 3 May 2024
- was granted 200,000 shares of Edgewise Therapeutics (a derivative holding)SEC Form 418 August 2023Stock Option (Right to Buy) · traded 17 August 2023 · filed 18 August 2023
- exercised options over 10,416 shares of Edgewise Therapeutics (a derivative holding)SEC Form 43 May 2023Restricted Stock Units · traded 1 May 2023 · filed 3 May 2023
- exercised options over 10,416 shares of Edgewise TherapeuticsSEC Form 43 May 2023Common Stock · traded 1 May 2023 · filed 3 May 2023
- ▼ sold on the open market 3,254 shares of Edgewise TherapeuticsSEC Form 43 May 2023Common Stock · traded 2 May 2023 · filed 3 May 2023
- was granted 240,000 shares of Edgewise Therapeutics (a derivative holding)SEC Form 410 August 2022Stock Option (Right to Buy) · traded 8 August 2022 · filed 10 August 2022
- was granted 31,250 shares of Edgewise Therapeutics (a derivative holding)SEC Form 43 May 2022Restricted Stock Units · traded 1 May 2022 · filed 3 May 2022
- was granted 160,000 shares of Edgewise Therapeutics (a derivative holding)SEC Form 419 August 2021Stock Option (Right to Buy) · traded 17 August 2021 · filed 19 August 2021
- was granted 160,000 shares of Edgewise Therapeutics (a derivative holding)SEC Form 44 May 2021Stock Option (Right to Buy) · traded 30 April 2021 · filed 4 May 2021
- was granted 60,000 shares of Catabasis Pharmaceuticals (a derivative holding)SEC Form 414 February 2020Stock Option (right to buy) · traded 12 February 2020 · filed 14 February 2020
- was granted 40,000 shares of Catabasis Pharmaceuticals (a derivative holding)SEC Form 415 February 2019Stock Option (right to buy) · traded 13 February 2019 · filed 15 February 2019
- was granted 150,000 shares of Catabasis Pharmaceuticals (a derivative holding)SEC Form 411 September 2018Stock Option (right to buy) · traded 7 September 2018 · filed 11 September 2018
- was granted 100,000 shares of Catabasis Pharmaceuticals (a derivative holding)SEC Form 49 February 2018Stock Option (right to buy) · traded 8 February 2018 · filed 9 February 2018
- was granted 100,000 shares of Catabasis Pharmaceuticals (a derivative holding)SEC Form 410 February 2017Stock Option (right to buy) · traded 9 February 2017 · filed 10 February 2017
- was granted 45,000 shares of Catabasis Pharmaceuticals (a derivative holding)SEC Form 413 September 2016Stock Option (right to buy) · traded 8 September 2016 · filed 13 September 2016
- was granted 45,000 shares of Catabasis Pharmaceuticals (a derivative holding)SEC Form 412 September 2016Stock Option (right to buy) · traded 8 September 2016 · filed 12 September 2016
- was granted 66,000 shares of Catabasis Pharmaceuticals (a derivative holding)SEC Form 416 February 2016Stock Option (right to buy) · traded 11 February 2016 · filed 16 February 2016
- converted 409 shares of Catabasis PharmaceuticalsSEC Form 430 June 2015Common Stock · traded 30 June 2015 · filed 30 June 2015
- converted 5,261 shares of Catabasis Pharmaceuticals (a derivative holding)SEC Form 430 June 2015Series B Preferred Stock · traded 30 June 2015 · filed 30 June 2015
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.